Clindamycin Injection — Class III drug recall D-1072-2019
Terminated recall by Pfizer Inc., reported 2019-04-10, distributed nationwide. Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for se
| Recall number | D-1072-2019 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2019-03-15 |
| Classified | 2019-03-29 |
| Reported by FDA | 2019-04-10 |
| Terminated | 2022-08-11 |
| Distributed | Nationwide (US) |
| Reason classes | specification failure |
| NDC | 47781-0621-94 |
| Lot numbers | T96398, T97492, W28567, W31813 |
| Expiration dates | 2019-04, 2019-07, 2019-09, 2019-10 |
Product
Clindamycin Injection, USP, 900 mg/6 mL (150 mg/mL), 6 mL vial, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA. NDC 47781-621-94
Reason for recall
Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1072-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.